FIGURE 7.

Consequences of neutrophil/CD8⁺ T cell depletion on riluzole antitumor effects. (A) LLC‐inoculated mice were injected with riluzole (9 mg/kg or 18 mg/kg) five times. Tumor sizes were measured every 2 days (n = 5). **/^## p < 0.01 (riluzole vs. control at day 12). (B) LLC‐bearing mice treated in seven ways: control (DMSO), riluzole, riluzole combined anti‐LY6G Ab, riluzole combined anti‐CD8 Ab, isotype IgG, anti‐CD8, and anti‐LY6G. Bars represent mean ± SEM. **/^## p < 0.01 (compared to riluzole alone at day 12). (C) Flow cytometry analysis of diffused CFSE‐tagged CD8⁺ T cells. CD8⁺ T cells were treated with anti‐CD3/CD28 combined with riluzole for 24 h. (D) CD8⁺ T cell proliferation rates after coculturing with intended neutrophils. Neutrophils from LLC‐bearing mice treated with/without riluzole (R). **p < 0.01 between intended groups. (E) Schematic presentation of the possible effects of glutamate on neutrophils in tumor microenvironment